Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Sarnaik, A. (Amod) | - |
dc.creator | Khushalani, N. (Nikhil) | - |
dc.creator | Chesney, J. (Jason) | - |
dc.creator | Kluger, H. (Harriet) | - |
dc.creator | Curti, B. (Brendan) | - |
dc.creator | Lewis, K. (Karl) | - |
dc.creator | Medina, T. (Theresa) | - |
dc.creator | Thomas, S. (Sajeve) | - |
dc.creator | Pavlick, A. (Anna) | - |
dc.creator | Whitman, E. (Eric) | - |
dc.creator | Martin-Algarra, S. (Salvador) | - |
dc.creator | Corrie, P. (Pippa) | - |
dc.creator | Hamid, O. (Omid) | - |
dc.creator | Lutzky, J. (Jose) | - |
dc.creator | Olah, J. (Judit) | - |
dc.creator | Weber, J.S. (Jeffrey S.) | - |
dc.creator | Larkin, J. (James) | - |
dc.creator | Shi, W. (Wen) | - |
dc.creator | DiTrapani, K. (Kelly) | - |
dc.creator | Qin, H. (Harry) | - |
dc.creator | Mirgoli, M. (Mariam) | - |
dc.creator | Wu, R. (Renee) | - |
dc.creator | Takamura, T. (Toshimi) | - |
dc.creator | Fardis, M. (Maria) | - |
dc.creator | Kirkwood, J.M. (John M.) | - |
dc.date.accessioned | 2023-05-15T10:16:15Z | - |
dc.date.available | 2023-05-15T10:16:15Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Sarnaik, A. (Amod); Khushalani, N. (Nikhil); Chesney, J. (Jason); et al. "Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update". Journal for immunotherapy of cancer. 8 (Suppl 1), 2020, | es_ES |
dc.identifier.issn | 2051-1426 | - |
dc.identifier.uri | https://hdl.handle.net/10171/66224 | - |
dc.description.abstract | Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both investigator and an independent review committee (IRC), are presented. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMJ | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Treatment options | es_ES |
dc.subject | Advanced melanoma | es_ES |
dc.subject | Inhibitors | es_ES |
dc.subject | Cell therapy | es_ES |
dc.title | Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | cc-by-nc-nd | es_ES |
dc.identifier.doi | 10.1136/LBA2019.18 | - |
dadun.citation.number | Suppl 1 | es_ES |
dadun.citation.publicationName | Journal for immunotherapy of cancer | es_ES |
dadun.citation.volume | 8 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.